On March 30, 2026, Seer, Inc. (Nasdaq: SEER) announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, regarding the inter partes review of U.S. Patent No. 11,435,360 B2. This patent, which covers methods for analyzing biological samples using engineered nano- and microparticles, faced challenges from PreOmics GmbH and Biognosys AG, subsidiaries of Bruker Corporation. The PTAB's decision upheld 23 claims of the patent, including five challenged claims and 18 unchallenged claims, affirming the validity of Seer's nanoparticle protein enrichment technology. The upheld claims are crucial for detecting proteins across a wide concentration range and relate to particle-related aspects of Seer's technology, which are essential for deep proteomic analysis. Omid Farokhzad, Chair and CEO of Seer, expressed confidence in the decision, stating that it reinforces the strength of their technology and the Proteograph platform. The upheld patent claims are expected to support Seer's ongoing innovation and market position in the field of proteomics. The PTAB's ruling allows Seer to continue leveraging its intellectual property to deliver advanced proteomic insights to its customers. The company has a robust portfolio of over 240 issued patents and pending applications worldwide, including 80 issued patents. The decision also opens the door for either party to appeal, with a notice of appeal required by May 25, 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.